ClinicalTrials.gg
RecruitingNCT05815927PROLoNgUpdated May 28, 2026

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

A Phase 3 interventional study of Pembrolizumab and stereotattic ablation radiotherapy (SABR) in Oligometastatic Squamous Cell Carcinoma of the Head and Neck, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Phase 3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Squamous Cell Carcinoma of Head and Neck by European Organisation for Research and Treatment of Cancer - EORTC — 1 open to participants now, 3 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · European Organisation for Research and Treatment of Cancer - EORTC.

Planned enrollment
5th of 17
200 · median 50
Started
2025
the only one that year
Phase 3
7 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Squamous Cell Carcinoma of Head and Neck by European Organisation for Research and Treatment of Cancer - EORTC, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 3, and was the 17th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

1 of the 17 studies in Squamous Cell Carcinoma of Head and Neck by European Organisation for Research and Treatment of Cancer - EORTC is open now, in 4 countries.

By country, each count listing its studies:

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Squamous Cell Carcinoma of Head and Neck by European Organisation for Research and Treatment of Cancer - EORTC, or all of them as a file.
02

Study summary

This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell carcinoma of the head and neck (SCCHN), histological confirmation of the primary disease at first diagnosis, and PD-L1 CPS ≥1. After eligibility check and signing informed consent, all patients will be prospectively enrolled in a 1:1 ratio between current standard of care treatment (pembrolizumab, Arm 1) vs. SABR + standard of care treatment (Arm 2) to oligometastases.

Any radical treatment to the synchronous primary/ recurrent primary tumor and/or involved cervical nodes (surgery or radiotherapy), as decided by the local tumor board/ treating physicians, should be completed prior to enrolment.Surgical removal of metastases is allowed for diagnostic purposes or for brain metastases, as long as these metastases count toward the total number of 5 and at least one metastasis is left for treatment with SABR. Such surgical procedures should be performed prior to enrolment.

03

Conditions studied

  • Oligometastatic Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Pembrolizumab
  • Stereotactic ablative radiotherapy
  • oligometastatic HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion Criteria:

  • Male/female participants who are at least 18 years of age on the day of signing
  • confirmed HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or cervical primary occult and histologically or radiologically confirmed oligometastatic disease. Histological characterization of one lesion is strongly recommended.
  • Patients with synchronous or metachronous oligometastatic disease according to the ESTRO/EORTC consensus (1-5 metastatic lesions, with or without primary/recurrent primary tumour and/or regional disease).
  • Amenable to systemic treatment for R/M SCCHN.
  • For patients with oropharyngeal cancer: HPV status using p16 IHC evaluated locally.
  • CPS of at least 1 as evaluated locally.
  • Staging not older than 12 weeks before enrolment.
  • All the 1-5 metastases must be amenable to SABR.
  • Eligible for treatment with pembrolizumab.
  • Have based on 1.1.
  • performance status of 0 to 1.
  • Participants must have recovered from all treatment-related toxicities to baseline or grade ≤1, such as from previous radiotherapy, systemic treatment or surgery, and not requiring for managing treatment-related side effects.
  • Adequate Organ Function Laboratory Values.
  • Before patient registration/enrolment, written informed consent must be given according to ICH/GCP, and national/local regulations.

Main exclusion Criteria:

  • Nasopharynx, sino-nasal, and salivary gland cancers are excluded.
  • In-field progression in \< 6 months after curative intended locoregional irradiation of the head and neck.
  • Lesions larger than 6 cm in the largest dimension as measured in the diagnostic CT or MRI scan for lesions outside the brain. Note: bone metastases over 6 cm may be included if in the opinion of the local radiation oncologist they can be treated safely and no inner organ is affected.
  • only.
  • Has received any previous radiotherapy to any of the 1-5 metastases that would be subject to SABR in the experimental arm unless the investigator agrees to treat only after discussion with the RTQA team.
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
  • Previously treated brain metastases that are radiologically non-stable. Patients with previously treated brain metastases, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention, can participate.
  • Known to imaging tracer or any product of contrast media and MRI contraindications.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Arm 1 : Standard of Care

    Pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease. Palliative radiotherapy to oligometastatic disease is allowed if necessary as per standard of care to relieve symptomatic disease and prevent complications. Recommended dose regimens are 1x 8 Gy, 5x 4 Gy and 10x 3 Gy. Planning technique and target volume definition should be according to institutional standards.No ablative-stereotactic dose and no boost techniques are allowed with the exception of CNS-metastases treatment.

    Drug: Pembrolizumab

  • Experimental
    Arm 2 : Standard of Care + stereotattic ablative radiation (SABR)

    The Experiemnt Arm consists of pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease in combination with SABR. For each oligometastatic lesion treatment, specific SABR fractions and targeted dose(Gy) should be used depending on the location of the lesion. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.

    Drug: Pembrolizumab · Radiation: stereotattic ablation radiotherapy (SABR)

Interventions

  • Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).

  • Radiationstereotattic ablation radiotherapy (SABR)

    Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.

    Also known as: SBRT

06

What researchers measure

Primary outcomes

  1. Progression-free survival by RECIST 1.1

    To assess whether SABR added to pembrolizumab improves progression-free survival in patients with HNSCC disease, PD-L1 CPS ≥1 and 1-5 metastatic lesions, as compared to pembrolizumab alone.

    Time frame: 2.6 years after first patient in

Secondary outcomes

  1. Overall survival

    To assess whether SABR added to pembrolizumab improves OS

    Time frame: 5.2 years after first patient in

  2. Disease-specific survival

    To assess whether SABR added to pembrolizumab improves disease-specific survival

    Time frame: 5.2 years after first patient in

  3. Time to disease progression

    To assess whether SABR added to pembrolizumab improves time to disease progression

    Time frame: 5.2 years after first patient in

  4. Time to development of new metastatic lesions

    To assess whether SABR added to pembrolizumab improves time to development of new metastatic lesions

    Time frame: 5.2 years after first patient in

  5. Time to progression in oligometastatic lesions initially present at enrolment

    To assess whether SABR added to pembrolizumab improves time to progression in oligometastatic lesions initially present at enrolment

    Time frame: 5.2 years after first patient in

  6. Adverse events according to CTCAE version 5.0

    To evaluate the safety and tolerability according to CTCAE v5.0 of SABR combined with pembrolizumab

    Time frame: 5.2 years after first patient in

  7. Health-related quality of life evaluated using self-administered EORTC QLQ-C30 questionnaire

    Time frame: 5.2 years after first patient in

  8. Health-related quality of life evaluated using self-administered EORTC QLQ-HN43 questionnaire

    Time frame: 5.2 years after first patient in

  9. Health-related quality of life evaluated using self-administered EORTC IL-198 questionnaire

    Time frame: 5.2 years after first patient in

07

Study locations

17 of 30 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 25 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Apr 18, 2023
StartActual
May 23, 2025
Primary completionEst.
Jul 15, 2027
CompletionEst.
Mar 30, 2030
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05815927
Collaborators
Swiss Cancer Institute, Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
May 23, 2025
Primary completion
Jul 15, 2027 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
May 28, 2026

Study contacts

EORTC HQ
Contact
eortc@eortc.org
+32 2 774 16 11
Panagiotis Belermpas, MD
study chair · University of Zurich
Jean-Pascal Machiels, MD
study chair · Clinicque Universitarie Saint Luc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion